# SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

> **NCT07482020** · PHASE2 · RECRUITING · sponsor: **Huashan Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)
- Hypertension

## Interventions

- **DRUG:** SGLT-2 inhibitors
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07482020
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482020, "SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07482020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*